The NIH experience with precocious puberty: Diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy

Ora Hirsch Pescovitz, Florence Comite, Karen Hench, Kevin Barnes, Ann McNemar, Carol Foster, Daniel Kenigsberg, Donald (Lynn) Loriaux, Gordon B. Cutler

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Between 1979 and 1983, 129 children (95 girls) with precocious puberty were referred to the National Institutes of Health and received treatment for at least 6 months with the long-acting LHRH analogue d-Trp6-Pro9-NEt-LHRH. The majority (107 of 129) of the children had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis in association with hypothalamic hamartomas (24 of 107) or other central nervous system lesions (21 of 107), or idiopathic precocious puberty (62 of 107). Hypothalamic hamartomas or other central nervous system lesions were a frequent cause of central precocious puberty in girls (27 of 87), but idiopathic precocious puberty was still the most frequent diagnosis (63%). Idiopathic precocious puberty was uncommon in boys (6%). The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty. These children had peripheral sex steroid secretion in the absence of hypothalamic-pituitary-gonadal axis maturation. The children with combined peripheral and central precocious puberty included nine children with congenital adrenal hyperplasia and one girl with a virilizing adrenal tumor. In the patients with central precocious puberty or combined peripheral and central precocious puberty, LHRHa therapy caused suppression of gonadotropin and sex steroid levels (Pa is an effective treatment of central precocious puberty and combined peripheral and central precocious puberty, but is ineffective in the therapy of peripheral precocious puberty.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalThe Journal of Pediatrics
Volume108
Issue number1
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Precocious Puberty
Gonadotropin-Releasing Hormone
Therapeutics
Central Nervous System
Steroids
Polyostotic Fibrous Dysplasia
Congenital Adrenal Hyperplasia
Glandular and Epithelial Neoplasms
National Institutes of Health (U.S.)
Central Precocious Puberty
Gonadotropins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The NIH experience with precocious puberty : Diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. / Pescovitz, Ora Hirsch; Comite, Florence; Hench, Karen; Barnes, Kevin; McNemar, Ann; Foster, Carol; Kenigsberg, Daniel; Loriaux, Donald (Lynn); Cutler, Gordon B.

In: The Journal of Pediatrics, Vol. 108, No. 1, 1986, p. 47-54.

Research output: Contribution to journalArticle

Pescovitz, Ora Hirsch ; Comite, Florence ; Hench, Karen ; Barnes, Kevin ; McNemar, Ann ; Foster, Carol ; Kenigsberg, Daniel ; Loriaux, Donald (Lynn) ; Cutler, Gordon B. / The NIH experience with precocious puberty : Diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. In: The Journal of Pediatrics. 1986 ; Vol. 108, No. 1. pp. 47-54.
@article{57c77011eea4432f95a4f26349312422,
title = "The NIH experience with precocious puberty: Diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy",
abstract = "Between 1979 and 1983, 129 children (95 girls) with precocious puberty were referred to the National Institutes of Health and received treatment for at least 6 months with the long-acting LHRH analogue d-Trp6-Pro9-NEt-LHRH. The majority (107 of 129) of the children had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis in association with hypothalamic hamartomas (24 of 107) or other central nervous system lesions (21 of 107), or idiopathic precocious puberty (62 of 107). Hypothalamic hamartomas or other central nervous system lesions were a frequent cause of central precocious puberty in girls (27 of 87), but idiopathic precocious puberty was still the most frequent diagnosis (63{\%}). Idiopathic precocious puberty was uncommon in boys (6{\%}). The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty. These children had peripheral sex steroid secretion in the absence of hypothalamic-pituitary-gonadal axis maturation. The children with combined peripheral and central precocious puberty included nine children with congenital adrenal hyperplasia and one girl with a virilizing adrenal tumor. In the patients with central precocious puberty or combined peripheral and central precocious puberty, LHRHa therapy caused suppression of gonadotropin and sex steroid levels (Pa is an effective treatment of central precocious puberty and combined peripheral and central precocious puberty, but is ineffective in the therapy of peripheral precocious puberty.",
author = "Pescovitz, {Ora Hirsch} and Florence Comite and Karen Hench and Kevin Barnes and Ann McNemar and Carol Foster and Daniel Kenigsberg and Loriaux, {Donald (Lynn)} and Cutler, {Gordon B.}",
year = "1986",
doi = "10.1016/S0022-3476(86)80767-3",
language = "English (US)",
volume = "108",
pages = "47--54",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - The NIH experience with precocious puberty

T2 - Diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy

AU - Pescovitz, Ora Hirsch

AU - Comite, Florence

AU - Hench, Karen

AU - Barnes, Kevin

AU - McNemar, Ann

AU - Foster, Carol

AU - Kenigsberg, Daniel

AU - Loriaux, Donald (Lynn)

AU - Cutler, Gordon B.

PY - 1986

Y1 - 1986

N2 - Between 1979 and 1983, 129 children (95 girls) with precocious puberty were referred to the National Institutes of Health and received treatment for at least 6 months with the long-acting LHRH analogue d-Trp6-Pro9-NEt-LHRH. The majority (107 of 129) of the children had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis in association with hypothalamic hamartomas (24 of 107) or other central nervous system lesions (21 of 107), or idiopathic precocious puberty (62 of 107). Hypothalamic hamartomas or other central nervous system lesions were a frequent cause of central precocious puberty in girls (27 of 87), but idiopathic precocious puberty was still the most frequent diagnosis (63%). Idiopathic precocious puberty was uncommon in boys (6%). The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty. These children had peripheral sex steroid secretion in the absence of hypothalamic-pituitary-gonadal axis maturation. The children with combined peripheral and central precocious puberty included nine children with congenital adrenal hyperplasia and one girl with a virilizing adrenal tumor. In the patients with central precocious puberty or combined peripheral and central precocious puberty, LHRHa therapy caused suppression of gonadotropin and sex steroid levels (Pa is an effective treatment of central precocious puberty and combined peripheral and central precocious puberty, but is ineffective in the therapy of peripheral precocious puberty.

AB - Between 1979 and 1983, 129 children (95 girls) with precocious puberty were referred to the National Institutes of Health and received treatment for at least 6 months with the long-acting LHRH analogue d-Trp6-Pro9-NEt-LHRH. The majority (107 of 129) of the children had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis in association with hypothalamic hamartomas (24 of 107) or other central nervous system lesions (21 of 107), or idiopathic precocious puberty (62 of 107). Hypothalamic hamartomas or other central nervous system lesions were a frequent cause of central precocious puberty in girls (27 of 87), but idiopathic precocious puberty was still the most frequent diagnosis (63%). Idiopathic precocious puberty was uncommon in boys (6%). The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty. These children had peripheral sex steroid secretion in the absence of hypothalamic-pituitary-gonadal axis maturation. The children with combined peripheral and central precocious puberty included nine children with congenital adrenal hyperplasia and one girl with a virilizing adrenal tumor. In the patients with central precocious puberty or combined peripheral and central precocious puberty, LHRHa therapy caused suppression of gonadotropin and sex steroid levels (Pa is an effective treatment of central precocious puberty and combined peripheral and central precocious puberty, but is ineffective in the therapy of peripheral precocious puberty.

UR - http://www.scopus.com/inward/record.url?scp=0022646469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022646469&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(86)80767-3

DO - 10.1016/S0022-3476(86)80767-3

M3 - Article

C2 - 3080571

AN - SCOPUS:0022646469

VL - 108

SP - 47

EP - 54

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 1

ER -